The trial met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival
The expansion includes a larger technical and service team and increased local procurement
The state-of-the-art facility is expected to be commissioned over the next three years
At one year, the drug met its primary and all key secondary endpoints, delivering significantly better weight maintenance than placebo
,_Thyrocare_256_384.jpg)
Dr Kinha is a seasoned healthcare and diagnostics leader with over 17 years of experience across leading organisations in the diagnostics sector, with deep expertise in laboratory operations and quality systems
The move strengthens GBL’s clinical-stage presence in the United States
Patients with BRCA mutations often face aggressive disease and poor prognosis
Convenient subcutaneous option has potential to reach more patients with same clinical benefits as Saphnelo IV infusion
Hansoh Pharma will receive an upfront payment in the low double-digit millions
Subscribe To Our Newsletter & Stay Updated
